Impressive Financial Growth of Ayurcann Holdings Corp.
Toronto, Ontario, Ayurcann Holdings Corp. (CSE: AYUR; OTCQB: AYURF) has released remarkable financial results, showcasing a gross revenue of $55,446,352 for the fiscal year ending June 30, along with a substantial year-over-year increase of 21%. Ayurcann, well-known for its prowess in the cannabis industry, specializes in manufacturing and processing cannabis 2.0 and 3.0 products, solidifying its position as a leader in the Canadian market.
Key Highlights from Fiscal Year 2025
The financial success is bolstered by several operational achievements. The company has displayed exceptional growth, maintaining a robust 100% increase in sales over the past three fiscal years, underlining its strategic focus and operational efficiency. The comprehensive growth trajectory indicates not only the company’s resilience but also their commitment towards customer satisfaction and brand loyalty.
Nationally Expanding Product Reach
Ayurcann has made significant strides in extending its product availability, now serving over 75% of licensed retail cannabis stores across Canada. This achievement indicates a potent national presence, ensuring that consumers from coast to coast can access Ayurcann’s diverse product portfolio easily.
Ontario Market Leadership
In Ontario, the largest cannabis market in Canada, Ayurcann has excelled with over 80% retail penetration, marking its products in more than 1,500 licensed stores. Strong partnerships with local retailers and the Ontario Cannabis Store have catalyzed Ayurcann's substantial market share acquisition, reinforcing its leading status.
Fiscal Year 2025 Financial Summary
- Gross Revenue: $55,446,352, up from $45,265,235 in FY 2024.
- Adjusted EBITDA: $507,570, rebounding from a negative $352,492 in FY 2024.
- Product Portfolio: Expanded to include 80 SKUs across various categories, effectively catering to a diverse clientele.
CEO Igal Sudman expressed optimism about the company’s future, emphasizing the demand for Ayurcann's brands across multiple provinces even amidst price pressures in the cannabis market. He highlighted Ayurcann’s proactive strategies, which enable the company to not just meet market needs but exceed customer expectations as well.
Operational Advancements in Year 2025
- Achieved over 35,500 product listings across various provinces including New Brunswick, Manitoba, Saskatchewan, Alberta, British Columbia, Newfoundland, and Yukon.
- Prioritized continual innovation and new product development to enhance the reliability of services.
- Maintained strong consumer demand levels across multiple product categories, including vape, concentrate, and flower.
- Invested progressively in operational efficiency, demonstrating commitment to improve the supply chain optimization and production scalability.
Sudman reiterated the company’s focus on innovation and reliably addressing market demands, which remains at the core of Ayurcann’s operations. The commitment to shareholding value along with domestic and international expansion highlights Ayurcann’s strategic vision moving forward.
Upcoming Changes in Corporate Structure
Ayurcann has announced a strategic decision to delist from the OTCQB Venture Market effective October 30, 2025, reinforcing a focused trading strategy in Canada under the ticker symbol “AYUR.” This step aligns with the company's long-term goals and operational strategies.
Contact Information
For further inquiries:
Igal Sudman, Chairman and Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322
Email: info@ayurcann.com
About Ayurcann
Ayurcann is a foremost post-harvest solution provider aiming to deliver state-of-the-art processes and pharmaceutical-grade products for both adult use and medical cannabis sectors. Dedicated to being a partner of choice for premier Canadian cannabis brands, Ayurcann offers top-notch services from extraction to product development, embodying quality and reliability.
Frequently Asked Questions
What were Ayurcann's total sales for the fiscal year ending 2025?
Ayurcann reported a gross revenue of $55,446,352 for the fiscal year ending June 30, 2025.
How has Ayurcann expanded its market presence?
The company has made its products available in over 75% of licensed retail cannabis stores across Canada.
What is the significance of Ayurcann's market position in Ontario?
Ayurcann has achieved over 80% retail penetration in Ontario, indicating strong relationships and significant market share within the largest cannabis market in Canada.
What strategic decisions were made regarding Ayurcann's stock trading?
The company announced its decision to voluntarily delist from the OTCQB Market effective October 30, 2025, while continuing trading in Canada.
What is Ayurcann's future vision?
Ayurcann aims for growth by enhancing operational efficiency, expanding market share, and maintaining strong brand loyalty and customer satisfaction.
